Long-Term Oncological Outcome Comparison between Intermediate- and High-Dose Radioactive Iodine Ablation in Patients with Differentiated Thyroid Carcinoma: A Propensity Score Matching Study
Table 2
Comparison of perioperative biochemical characteristics between intermediate- (100 mCi) and high-dose (150 mCi) groups before and after propensity score matching.
Before matching
value
After matching
value
100 mCi (n = 1146)
150 mCi (n = 302)
100 mCi (n = 1146)
150 mCi (n = 302)
Pre-op. TSH (mIU/L)
2.9 ± 10.9
2.2 ± 1.8
0.276
2.1 ± 1.5
2.2 ± 1.8
0.549
Pre-op. serum Tg (ng/mL)
30.9 ± 75.6
39.7 ± 89.4
0.086
38.7 ± 99.9
39.9 ± 92.4
0.885
≤1
114 (9.9%)
30 (9.9%)
1.000
30 (10.9%)
28 (10.1%)
0.890
>1
1032 (90.1%)
272 (90.1%)
246 (89.1%)
248 (89.9%)
≤10
505 (44.1%)
109 (36.1%)
0.013
111 (40.2%)
99 (35.9%)
0.335
>10
641 (55.9%)
193 (63.9%)
165 (59.8%)
177 (64.1%)
Pre-op. serum TgAb (IU/mL)
113.7 ± 595.9
207.0 ± 884.2
0.031
170.5 ± 889.8
144.3 ± 569.0
0.681
Negative
922 (80.5%)
235 (77.8%)
0.333
225 (81.5%)
216 (78.3%)
0.396
Positive
224 (19.5%)
67 (22.2%)
51 (18.5%)
60 (21.7%)
Post-RAI serum Tg (ng/mL)
3.8 ± 12.5
9.8 ± 41.2
<0.001
5.3 ± 13.7
6.7 ± 15.9
0.263
≤1
665 (58.0%)
154 (51.0%)
0.031
141 (51.1%)
144 (52.2%)
0.865
>1
481 (42.0%)
148 (49.0%)
135 (48.9%)
132 (47.8%)
≤10
1048 (91.4%)
246 (81.5%)
<0.001
245 (88.8%)
229 (83.0%)
0.066
>10
98 (8.6%)
56 (18.5%)
31 (11.2%)
47 (17.0%)
Post-RAI serum TgAb (IU/mL)
31.1 ± 100.9
64.2 ± 324.8
0.003
44.5 ± 163.9
35.6 ± 133.3
0.484
Negative
1067 (93.1%)
272 (90.1%)
0.086
252 (91.3%)
252 (91.3%)
1.000
Positive
79 (6.9%)
31 (9.9%)
24 (8.7%)
241 (8.7%)
Data are expressed as the patient’s number (%) or mean ± SD. A statistically significant difference was defined as . Negative TgAb, TgAb <60 IU/mL; positive TgAb, TgAb ≥60 IU/mL. Abbreviation: TSH, thyroid-stimulating hormone; pre-op, preoperative; post-RAI, after radioactive iodine therapy; Tg, thyroglobulin; TgAb, thyroglobulin antibody.
